# Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

> **NCT03045497** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 15 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Perflutren Lipid Microspheres
- **DEVICE:** Dynamic Contrast-Enhanced Ultrasound Imaging
- **DEVICE:** Contrast-enhanced Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT03045497
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-12
- **Primary completion:** 2013-12-05
- **Final completion:** 2013-12-05
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045497, "Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03045497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*